Sulfateq B.V. has multiple compounds in development for major burden diseases. Our pipeline consist of compounds in development for Acute Kidney Injury (AKI)Diabetic Kidney DiseaseChronic Obstructive Pulmonary Disease (COPD)and Pulmonary Arterial Hypertension (PAH). SUL-138, our lead compound, is at the end of the pre-clinical phase.

  • SUL-138 | Acute Kidney Injury
  • SUL-121 | Type II Diabetes
  • SUL-121 | COPD
  • SUL-150 | Pulmonary Arterial Hypertension

Contact us